In 1993, Antonio Giordano, M.D., Ph.D., founded the Sbarro Institute with a generous donation from Mario Sbarro, the Founder of the Sbarro restaurant chain, following Dr. Giordano’s discovery of the tumor suppressor gene pRb2. Initially named the Sbarro Institute, the research center was located at Thomas Jefferson University, where Dr. Giordano was a professor. When Dr. Giordano moved to Temple University in 2002, he and twenty fellow scientists forged a new, three-year alliance with Temple University in Philadelphia, Pennsylvania. Under the new arrangement, the original Sbarro Institute was renamed the Sbarro Health Research Organization, Inc. (SHRO), which includes the Sbarro Institute for Cancer Research and Molecular Medicine at Temple and the SHRO-affiliated laboratory at the University of Siena in Siena, Italy. Under a 2005 agreement, the Sbarro Institute for Cancer Research and Molecular Medicine received continued funding from Temple and expanded its program to include work on the relationship between obesity and cancer and instituted a new program on molecular therapeutics to explore how molecular genetic research can be applied to patient therapies and diagnostics. SHRO relies on grants and private donations to fund important biomedical research.
Dr. Herbst’s primary mission is the enhanced integration of clinical, laboratory, and research programs to bring new treatments to cancer patients. He has led the Phase I development of several of the new generation of targeted agents for non-small cell lung cancer (NSCLC), including gefitinib, erlotinib, cetuximab, and bevacizumab. More recently, he participated in the successful registration of pembrolizumab for the treatment of advanced non-small cell lung cancer, following the successful Yale-led KEYNOTE 10 study of the immune therapy drug commonly used to treat other cancers. He was co-leader for the BATTLE-1 clinical trial program, co-leads the subsequent BATTLE-2 clinical trial program, and served as a Co-program Leader of the Developmental Therapeutics Program for the YCC Support Grant. Dr. Herbst’s laboratory work is focused on immunotherapy angiogenesis; dual epidermal growth factor receptor (EGFR)/vascular endothelial growth factor receptor (VEGFR) inhibition in NSCLC, and targeting KRAS-activated pathways. More recently, he has explored predictive biomarkers for the use of immunotherapy agents. This work has been translated from the preclinical to clinical setting in multiple Phase II and III studies which he has led. After earning a B.S. and M.S. degree from Yale University, Dr. Herbst earned his M.D. at Cornell University Medical College and his Ph.D. in molecular cell biology at The Rockefeller University in New York City, New York. His postgraduate training included an internship and residency in medicine at Brigham and Women’s Hospital in Boston, Massachusetts. His clinical fellowships in medicine and hematology were completed at the Dana-Farber Cancer Institute and Brigham and Women’s Hospital, respectively. Subsequently, Dr. Herbst completed a M.S. degree in clinical translational research at Harvard University in Cambridge, Massachusetts. Dr. Herbst is an author or co-author of more than 275 publications, including peer-reviewed journal articles, abstracts, and book chapters. His work has been published in many prominent journals, such as the Journal of Clinical Oncology, Clinical Cancer Research, Lancet, the New England Journal of Medicine, and Nature. His abstracts have been presented at the annual meetings of the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research (AACR), the World Conference on Lung Cancer, the Society of Nuclear Medicine Conference, and the European Organization for Research and Treatment of Cancer. Dr. Herbst was a member of the National Cancer Policy Forum (1998-2014) for which he organized an Institute of Medicine meeting focused on policy issues in personalized medicine. He is a member of ASCO and, as a member of AACR, he chairs the Tobacco Task Force. He is a fellow of the American College of Physicians and an elected member of the Association of American Physicians. Dr. Herbst is also a member of the medical advisory committee for the Lung Cancer Research Foundation and chair of the communications committee for ASCO and the International Association for the Study of Lung Cancer. He is currently the Vice Chair for Developmental Therapeutics for the Southwestern Oncology Group (SWOG) Lung Committee, Principal Investigator of the SWOG 0819 trial, and steering committee chair for the Lung Master Protocol (Lung MAP). Dr. Herbst was awarded the 2010 Waun Ki Hong Award for Excellence in Team Science by the Division of Cancer Medicine, UT-MDACC. The Alvin S. Slotnick Lecture Award for notable contributions to lung cancer research was bestowed upon him by Dana-Farber/Brigham and Women’s Cancer Center in 2014. That same year, the Bonnie Addario Foundation honored him with the Annual Addario Lectureship Award and the Bonnie J. Addario Excellence in Collaboration and Innovation Award. In 2015, the Clinical Research Forum presented his project “Predictive Correlates of Response to the Anti-PD-L1 Antibody MPDL3280A in Cancer Patients” its top Clinical Research Achievement Award in the United States for 2015. For his lifetime achievement in scientific contributions to thoracic cancer research, Herbst was awarded the 2016 Paul A. Bunn, Jr. Scientific Award by the International Association for the Study of Lung Cancer at IASLC 17th World Conference on Lung Cancer in Vienna, Austria. His work has been funded by ASCO, AACR, the United States Department of Defense, and the National Cancer Institute. In 2015, his team at Yale was awarded a lung cancer SPORE by the NCI, and he serves as a principal investigator for the AACR/ Stand Up to Cancer Dream Team grant. EDUCATION & TRAINING MMS Harvard University, Clinical Translational Research (1997) MD Cornell University Medical College (1991) PhD Rockefeller University (1990) BS Yale University, Molecular Biophysics & Biochemistry (1984) MS Yale University, Molecular Biophysics and Biochemistry (1984) Fellowship Brigham and Women`s Hospital Fellowship Dana Farber Cancer Institute Residency Brigham and Women`s Hospital HONORS & RECOGNITION Elected to the Association of American Physicians AAP (2015) Addario Foundation Lectureship Award Bonnie Addario Foundation (2014) Alvin S. Slotnick Lecture Award for notable contributions to lung cancer research Dana-Farber/Brigham and Women’s Cancer Center (2014) Best Doctors, New York Magazine (2014) Honorary Professor, University College London Cancer Center University College London (2012) Sikand Orator Yale University (2011) PROFESSIONAL SERVICE National Cancer Institute (2012 - Present) Thoracic Malignancy Steering Committee - National Cancer Institute
Deputy Director, Chair of Gynecologic Oncology and the M. Steven Piver Professor of Gynecologic Oncology, Roswell Park Cancer Institute Areas of expertise: Ovarian cancer, uterine cancer, cervical cancer, vaginal cancer, vulvar cancer, women’s cancers, immunotherapy, cancer vaccines, cancer therapies
Director, The Hoffberger Breast Center at MercyMercy Medical Center
Cancer, Breast Cancer, Research, Womens Health, intraoperative radiotherapy
Neil B. Friedman, M.D., FACS, is Director of The Hoffberger Breast Center at Mercy as well as Medical Director of The Weinberg Center for Women's Health and Medicine at Mercy. As a catalyst for advancing breast cancer treatment, Dr. Friedman has partnered with many prestigious national and local organizations to improve the treatment options for women with breast cancer. Likewise, on a very personal level, he partners with each of his patients and their families to help them face the challenges and triumphs of living with a breast cancer diagnosis. Dr. Friedman led the charge to bring IORT, Intraoperative Radiotherapy, to Mercy making it the first hospital in Maryland to offer this leading-edge technology. Dr. Friedmane began his medical career as Chief Resident at the nationally renowned Memorial Sloan-Kettering Cancer Center in New York. He is a Board Certified breast cancer doctor who is dedicated to the search for a cure for cancer. His team continues to lead breast cancer initiatives and introduce best-in-practice breast care treatment options, including Intraoperative Radiotherapy (IORT), an innovative, single-dose radiation treatment, to patients. Dr. Friedman was named Humanitarian of the Year by the Mildred Mindell Cancer Foundation for his efforts in the fight against breast cancer. He has served as a national spokesperson for breast cancer prevention for major organizations such as Bath & Bodyworks. Dr. Friedman has been the Chairman of the American Cancer Society’s Research Administrative Committee, a member of its Executive and Professional Education Committees, and served on its Board of Directors. He has also been involved with the Susan G. Komen Breast Cancer Foundation. Dr. Friedman leads a team of clinicians devoted to breast cancer education, advocating the latest advancements in diagnosis and treatment of breast cancer at a number of conferences, continuing education forums, and patient seminars. Dr. Neil Friedman remains committed in his career to find optimal treatments for breast cancer. Some of his accomplishments include: • Named a “Top Doc” by Baltimore magazine in the Breast Surgery category • Named Humanitarian of the Year by the Mildred Mindell Cancer Foundation • The Breast Center at Mercy Medical Center first in Maryland to offer IORT Treatment • Research on cancer has been published in American Journal of Public Health(APHA) and the Journal of Immunotherapy
Medical Director, The Institute for Cancer Care atMercy Medical Center
Thyroid Cancer, Oncologist, Hyperthermic Intraperitoneal Chemotherapy, Cancer, medical director
Armando Sardi, M.D., is a respected and renowned Surgical Oncologist who has been honored as a Top Doc in Baltimore magazine multiple times. He serves as Medical Director of The Institute for Cancer Care at Mercy and as Chief of Division of Surgical Oncology at Mercy Medical Center in Downtown Baltimore, Maryland. Dr. Sardi is one of Maryland’s leading surgical oncologists who use Hyperthermic Intraperitoneal Chemotherapy (HIPEC) to treat late-stage, complex cancers of the abdominal region. Dr. Sardi has been performing HIPEC procedures since 1994 and is considered to be among the best doctors using the technique. This advanced heated chemotherapy procedure is often a life-saving treatment option for patients who have exhausted more traditional treatment plans for stomach cancer. Patients have traveled to Mercy Medical Center from points up and down the East Coast to destinations across the U.S., to seek out Dr. Sardi for his cancer expertise in the HIPEC treatment. Dr. Armando Sardi is a man whose professional focus is devoted to medical excellence, research and finding a cure for cancer. For his patients, Dr. Sardi’s personal concern and approach to their care are what helps them gain a positive outlook and confidence to face the challenges ahead. His cheerful smile and kind-hearted laugh immediately put patients at ease. And yet, his unyielding determination to give every patient the best possible chance to overcome their illness that ranks him among the best of the best. When other doctors have told patients there is no hope, Dr. Sardi tries even harder to beat the odds. Thanks to Dr. Sardi, the HIPEC procedure and other leading-edge treatment options, he has given patients so much more than hope. Patient after patient, year after year, have shared their stories at Mercy’s National Cancer Day Survivor Celebration and Mercy's annual Heat It to Beat It fundraising event. There are 3, 5, 10-year cancer survivors – each telling a heartwarming story of hope and survivorship. Dr. Sardi co-chair Mercy’s Cancer Committee and actively participates in The Tumor Board. These efforts allow cancer experts, specialists and key members of the healthcare team to discuss and collaborate on complex cancer cases to learn new and different ways to optimize resources, medical knowledge and treat patients so that long-term results will be improved. Dr. Sardi also plays a key role in the Mercy National Cancer Survivor Day festivities. This joyous and spirited celebration is more than a reunion of cancer survivors, it is a day when Dr. Sardi and the Mercy family rejoice with their patients and loved ones. Together they have been through a long and challenging cancer journey and together they delight in all the possibilities ahead. Dr. Armando Sardi, whose celebrated reputation has garnered local and international acclaim, has earned an international reputation for the advances he has made in the surgical oncology field and for his humanitarian efforts to care for the poor and underserved in third world countries. Dr. Sardi has been distinguished in Colombia, South America as one of the 100 Most Influential Expatriates – an honor received, in part, for the medical care he provides through the non-profit organization, Partners for Cancer Care and Prevention. This organization was the recipient of the Conquer Cancer Foundation's Inaugural International Innovation Grant. Dr. Armando Sardi has been recognized for his research, leadership and compassionate bedside manner. Some of his awards include: “Hispanic Hero Award for Excellence as a Medical/Social Entrepreneur” Presented by USHYEE “Gold Star Teamwork Award” Presented by The Sisters of Mercy in recognition of Gold Star performance Honored by Fusionarte as one of “100 Colombianos” who represent the talent, creativity, and perseverance of Colombia. Bogota, Colombia December 2012 Named by Baltimore Magazine a "Top Doctor" in the Surgical Oncology specialty Named by Castle Connelly Medical Ltd. a "Top Doctor" in Surgery Dr. Sardi founded the annual HEAT IT TO BEAT IT benefit walk in Baltimore to raise awareness about HIPEC and cancer treatment.